Think Tank on TROP-2 Therapy in NSCLC: A Look to the Future

Get up to date on emerging TROP-2–targeted antibody–drug conjugates for the treatment of advanced NSCLC with this comprehensive educational program, including expert-authored commentaries, a text module with a downloadable slideset capturing a panel discussion among 5 lung cancer experts, and a guided infographic on adverse event management with these agents.

Share

Program Content

Call to Action: TROP2 ADCs in Lung Cancer
Call to Action: Misperceptions on TROP2-Targeted Antibody–Drug Conjugates in Lung Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 24, 2023

Expires: February 23, 2024

View Activity
TROP2 ADC + IO in NSCLC
Combination Therapy With TROP2-Targeted Antibody–Drug Conjugates and Immunotherapy in Advanced/Metastatic NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 03, 2023

View Activity
TROP2 ADC Toxicities
Managing the Toxicities of TROP2 Antibody–Drug Conjugates in Lung Cancer
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2023

View Activity

Faculty

cover img faculity

Rebecca S. Heist, MD MPH

Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

cover img faculity

Stephen Liu, MD

Stephen Liu, MD 
Associate Professor of Medicine 
Medical Oncology 
Director of Thoracic Oncology 
Lombardi Comprehensice Cancer Center 
Georgetown University
Washington, D.C. 

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.